Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Genentech |
---|---|
Information provided by: | Genentech |
ClinicalTrials.gov Identifier: | NCT00281697 |
This Phase III, multicenter, randomized, placebo-controlled, blinded trial is designed to evaluate the efficacy and safety of bevacizumab when combined with standard chemotherapy compared with chemotherapy alone in subjects with previously treated MBC.
Condition | Intervention | Phase |
---|---|---|
Metastatic Breast Cancer |
Drug: bevacizumab Drug: chemotherapy Drug: placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment |
Official Title: | A Phase III, Multicenter, Randomized, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy Regimens in Subjects With Previously Treated Metastatic Breast Cancer |
Estimated Enrollment: | 650 |
Study Start Date: | February 2006 |
Estimated Primary Completion Date: | April 2010 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental |
Drug: bevacizumab
Intravenous repeating dose
Drug: chemotherapy
Repeating dose
|
2: Placebo Comparator |
Drug: chemotherapy
Repeating dose
Drug: placebo
Intravenous repeating dose
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Jai Balkissoon, M.D. | Genentech |
Responsible Party: | Genentech, Inc. ( Jai Balkissoon, M.D., Study Director ) |
Study ID Numbers: | AVF3693g |
Study First Received: | January 23, 2006 |
Last Updated: | September 22, 2008 |
ClinicalTrials.gov Identifier: | NCT00281697 |
Health Authority: | United States: Food and Drug Administration |
Ribbon 2 Avastin MBC Breast Cancer |
Skin Diseases Breast Neoplasms Bevacizumab Breast Diseases |
Neoplasms Neoplasms by Site Antineoplastic Agents Therapeutic Uses Growth Substances |
Physiological Effects of Drugs Growth Inhibitors Angiogenesis Modulating Agents Angiogenesis Inhibitors Pharmacologic Actions |